Diacylglyceride O-acyltransferase 2 inhibitors
Invented are compounds of formula I and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.
1. A compound of Formula I,
or a pharmaceutically acceptable salt thereof, wherein
R 1 is
R 2 is
and
R 3 is
2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, which is
3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, which is
4. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, which is
5. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, which is
6. The compound of claim 1 , or a pharmaceutically acceptable salt thereof, which is
7. A composition comprising a pharmaceutically acceptable carrier and a compound according to claim 1 , or a pharmaceutically acceptable salt thereof.
8. A method for treating a condition selected from hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases and heart failure comprising administering to a patient in need thereof a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
9. A compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein
R 1 is
(a) phenyl optionally substituted with one to three substituents independently selected from halogen, hydroxy, N(C 1-3 alkyl) 2 , CN, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, OC 1-6 alkyl, OC 1-6 haloalkyl, OC 3-6 cycloalkyl, S(O) 2 C 1-6 alkyl, OC 1-6 alkyl-CN, C 1-6 alkyl-CN, or NHC(O)C 1-6 alkyl, and wherein the cycloalkyl is optionally substituted with C 1-6 alkyl, C 1-6 haloalkyl, CN, OH, or OC 1-6 alkyl;
(b) 6 membered heteroaryl containing one nitrogen atom optionally substituted with one to three substituents independently selected from halogen, hydroxy, C 1-6 alkyl, C 1-6 haloalkyl, C 3-6 cycloalkyl, OC 1-6 alkyl, OC 1-6 haloalkyl, O—C 3-6 cycloalkyl, OC 1-6 alkyl-CN or CN, and when the cycloalkyl is cyclopropyl, the cyclopropyl is optionally substituted with halogen, C 1-6 alkyl, C 1-6 haloalkyl, CN, OH, or OC 1-6 alkyl; or
(c) 5 membered heteroaryl containing 2 N atoms optionally substituted with C 1-6 alkyl;
R 2 is:
(a) 4 to 6 membered heterocycle containing one oxygen atom optionally mono-substituted or disubstituted with halogen, C 1-6 haloalkyl, C 1-6 alkyl, C(O)C 1-6 alkyl, or OH, or
(b) C 1-6 alkyl unsubstituted or optionally mono-substituted, disubstituted or trisubstituted with halogen, OH, CF 3 , or CN; and
R 3 is a 4, 5, or 6 membered heterocyclyl containing 1 sulfur atom optionally mono-substituted, disubstituted, trisubstituted, or quad-substituted with oxo, CH 3 , or OH.
10. The compound of claim 9 of Formula I,
or a pharmaceutically acceptable salt thereof, wherein
11. A composition comprising a pharmaceutically acceptable carrier and a compound according to claim 9 , or a pharmaceutically acceptable salt thereof.
12. The compound of claim 9 , or a pharmaceutically acceptable salt thereof, which is:
13. A method for treating a condition selected from hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases and heart failure comprising administering to a patient in need thereof a compound of claim 9 , or a pharmaceutically acceptable salt thereof.